Podcasts about GE Healthcare

Preena: Welcome to the Weinberg in the World Podcast, where we bring stories of interdisciplinary thinking in today's complex world. My name is Preena Shroff and I'm your student host of this special Weinberg in the World episode. I'm a third year student majoring in neuroscience and global health studies with a minor in data center. Today I have the pleasure of speaking with Natasha Phillips, who graduated from Weinberg College in 2000 with a Bachelor of Arts in sociology and biology. Natasha currently serves as chief marketing officer for GE Healthcare, leading teams that help healthcare providers design treatment plans for their patients. Natasha, thank you so much for being here with us today. Natasha: Thanks for having me, Preena. It's a pleasure. Preena: We are so excited to learn about your work in healthcare marketing, but would love to start out with how your career path was shaped by your time at Northwestern. Maybe you can tell us more about your undergraduate experience, what were some impactful classes, extracurriculars, or mentorships opportunities that you had which impacted your post-graduate career? Natasha: Yeah. You're making me think a little bit, because I got to go back in time. As an undergraduate, I was super lucky, having both a biology and a sociology major, it gave me the ability to see a very wide range of classes. I wasn't 100% sure actually what I wanted to do. I knew I was somewhat interested in the sciences. I didn't actually know I would be that interested in the social sciences, but I took a couple of classes. One in particular was the Sociology of Race and Ethnicity with Charlie Moskos, which actually made me decide to ... That was the reason I became a sociology major. I just got super lucky, I loved that class. It's funny, if I ever had a second life, I always say I would have loved to have gone back and been a sociology professor. But I didn't take that path, I went more with the actual biology side of things. I was weighing, do I want to do research? I actually was really interested in molecular biology, primarily because in the late '90s, which is a very long time ago to our students who are listening, but for me that was a time very formative because they were sequencing the human genome. There was a lot of promise in the space, not only of biology, but more specifically molecular biology and how it is linked to genetics and genomics as we think about the impact on healthcare. That really interested me to the point where I really was considering actually getting my PhD in molecular biology. Some of my favorite classes were the ones in which I had exposure to research, because I got to see the importance of just the impact that research can have. And the ability to be able to find a practical application, even if it's on a very specific question, to really contribute to the body of knowledge. Ultimately ended up being unsure what I wanted to do right after undergrad, so I went into healthcare consulting in which I wanted to be able to figure out, do I want to go towards the more business side of healthcare and thinking about commercializing healthcare and science from the industry side of things? Or to the academic side and actually get my PhD, and think about contributing to science and healthcare in that realm. I did have exposure, both in consulting as well as in research. I started in a research program at the University of Chicago in molecular biology after doing consulting so I could see both sides. And ultimately, actually, that was when I made the decision to focus much more so on the business side of it and to get my MBA, and to move into healthcare marketing. That led me into the career in which I've had today, in which I've been very lucky to have over 15 years working at very large multinational healthcare companies, primarily in sales and marketing roles, bringing innovation in healthcare to people all over the globe. Preena: Absolutely. Wow, yeah. I think your path is actually not only a common path that students seek out, but also something that students might end up finding themselves in, even if they do experience a career switch in their life. That's really interesting to hear about. I have another question for you, more specifically job-oriented. Healthcare is constantly evolving, so maybe you can tell us a little bit about how your marketing approach has changed since you began your career? Natasha: Yeah. I love that question, Preena, because what really is happening is healthcare is evolving and the function of marketing is evolving constantly. I am really lucky that, both in the subject matter that I basically have decided to focus in, which is healthcare and ultimately the innovation around healthcare, but also have a really cool and exciting function that continues to evolve. I was lucky enough during my ... Maybe I'll start with the functional part, I'll start with marketing first, and then I'll talk about healthcare. The basic function of marketing has changed significantly over the past 20 years as I've been a marketer, primarily with the advent of digital and social media. It continues now to evolve, as we think about personalized marketing and AI, and what that's going to do. I would say the main changes that I've seen over time has been from a very I would say structured, one size fits all, if you think about it like mass media type of marketing in which there was a time in which you had one singular message and one singular way of approaching individuals, and not a lot of channels to reach them. To now, moving to almost a fully personalized marketing experience, where you have the ability with technology today to be able to say, even if you have thousands of targets, how do you understand the fine differences. There's got to be some generalization amongst those targets, but there's also some fine differences in how people consume their information, care about interacting with your brand, and want to be able to either become loyal brand advocates or detractors. How do you understand what those insights are to create an ongoing personalized journey that evolves over time with the individual as their media consumption and interest in whatever product you're selling changes? That's been one of the coolest innovations to think about, as we think about the function. If I look at healthcare, I've been lucky enough to see innovation across a variety of different segments within healthcare. I'd seen the advent of biologics. If we think about innovation from a healthcare point of view, in basically the last 20 years or so, we've seen drugs like Humira, which started the biologic class and has now exploded into one of the largest categories or segments within healthcare. And the significant impact that that has had on millions of patients, and has changed diseases all the way from skin conditions to much more serious autoimmune type of conditions. I've been lucky enough to see innovation on the diagnostic side, in which I've seen the advent of brand new technologies, including things like multi-plexing. Of taking a single sample, and instead of wanting to get one answer, you can get anywhere from 25 to 30 answers of which virus of which disease somebody has. And the impact that that has had not only on just healthcare, but on infectious disease and vaccines in other parts. For me, what has actually kept me so motivated in healthcare for so long is it isn't just an idea. I get to be part of the teams, and it's a cross-functional team that includes everybody from scientists, research and developers, operations, medical affairs, clinical affairs, marketers, salespeople, finance people, and everybody, I'm sure I'm forgetting some functions. It is such a complex effort to bring innovation like this to market and sometimes can take 10 to 15 years, but when it happens you actually see significant change in healthcare. For me, that's the ability to think even 30, 40 years from now, some of the either diagnostics, devices, or drugs that I've helped to bring to market will really have an impact. Either because it continues to improve healthcare or it was the precursor of future innovation that's going to continue to come because we've paved the way for it, so it's really cool. Preena: Absolutely. That's really incredible. And the way you're able to work with people of many different fields and backgrounds, and then learn from them as well is a really incredible experience, and I hope defines a lot of students' careers in the future as well. Natasha: Yeah. I think just to add to that, the one thing to really keep in mind is I love the interdisciplinary approach that a really good college in arts and sciences like Weinberg does. Because for me, that kind of thinking, although I didn't understand it at the time because I was just a student and I had no clue what I was actually going to do, is something that to this day in my career I think back to and I leverage. It's helped to make me successful, especially in a very large matrix cross-functional organization. It's something that, as all of you who are students potentially listening to this and are thinking, "What might I do in the future?" Really leverage the opportunities that you have to do that kind of interdisciplinary type of work because it will make you much stronger in whatever field you decide to do. Preena: Yeah, absolutely. Going off of that, a bit in the other direction, but what is a common misconception about working in the healthcare marketing industry? Natasha: That is a great question. This is maybe a little controversial, but I'm going to say it. I think there is this perception of big, bad pharma and big, bad healthcare. I think it's something that is an understandable point of view and one which requires probably much more dialogue than what we can answer here. But I'll just leave people with this one thought. Which is if you think about most of the major innovations that have come to healthcare over the last 30 years, whether it's drugs to treat high blood pressure or hypertension, or innovations in diagnostics as I mentioned to be able to not just understand what's happening from blood count, but to be able to look at the molecular and cellular level to treat rare diseases and everything in the middle. Much of that innovation, while it is funded and founded in the basic research that happens at academic and other institutions, has really been driven by the industry. Whether it's the pharmaceutical industry, the med device industry, the diagnostic industry. That requires significant investment and significant time. It also requires a very high failure rate. In some cases, if you have 100 compounds or 100 ideas that you're bringing through, less than 1% of them will sometimes make it to market. There is a significant amount of investment that needs to happen. While there's always optimizations that could happen, I always implore people to think about the fact that the drug that your mother or father is taking today, or that your brother or sister is taking for asthma, didn't exist probably even 20 or 30 years ago because we didn't have the funding and innovation that was coming necessarily maybe from companies that has been pushing that forward. While there is a lot of discussion to be had about healthcare and the rights to healthcare, I think companies like mine, whether it's my current company or previous company, have played a very important role in really helping to improve overall health and healthcare as we think about the impact on people's lives. I just ask people to be open to the fact that there's always a variety of different vantage points and it's always a great healthy dialogue to have. Preena: Of course, yeah. From what you said, it sounds like it's a bit of a trade-off and it's really important to discover where you fit in within that sphere, and learn how to interpret your work and your path in that direction as well. Just realizing what impact you're making and picturing that longterm. Natasha: Yeah, exactly. Preena: Okay. Then, I was also going to ask you about the student perspective, thinking about students today. How would you recommend students cultivate a personal brand? A lot of times people say networking. How do students network authentically, both online and in-person so that they can find the right opportunities or even the right opportunities can find them? Natasha: Yeah, I think it's a really great question. I very much will reiterate the importance of networking because I think that's foundational and fundamental to everything that we do today. In fact, many of you who got into very competitive colleges probably had to figure that out as you were even thinking about how to get into the school that you're in today. That thought process needs to continue as you think about getting your first job, or maybe you're getting your next pre-professional school that you're focused on. I would take that networking to the next step to say I think some of the most effective networking has two really good components. I find this, because I have a lot of people who maybe reach out to me, either through my network or because they're looking for learning about marketing or healthcare, or other topics that maybe I've had some experience with. The first of those two things is really having a genuine brand, and one in which you really own and feel passionate about. The most interesting and coolest networking that I do, even with students today, are the ones in which people are very purposeful about what they are interested in, what they care about, what their brand is. It's probably hard to even think about me as a college student, what is my brand? But you have a brand. You may not know it yet, but you definitely have and can develop a brand. That brand should be whatever you feel truly passionate and genuinely interested in, because that will only I would say help you have much more successful networking and much more genuine connections with the people that you are trying to connect with. Even if that individual maybe doesn't understand or isn't that maybe close to the topic, you'd be shocked how just that genuine authenticity is going to help drive really stronger connections in networking that are going to help both you, as well as the network that you're creating, as you think about the fact that one day you're going to have a network and you're going to want to be able to pay it forward to students the way maybe people are helping you with your decisions and career today. The second one as you think about networking is a lot of times, networking and finding a good fit, whether it's a company or your next pre-professional program, or what you even want to do, is based on having a shared purpose with whoever you're networking with or whatever that institution is. I find the people who come and are most prepared for interviews, in addition to feeling very genuine and knowing what their brand is, are the people who are very clear on what my purpose, either as an institution is, or whatever group I'm part of. They understand that and it is very much akin to who they are, what they're looking for, what makes them passionate. That sense of shared purpose in networking I think is another way in which you can more successfully think about how do you take your decisions or whatever you're going to do next in your career path and be more successful in terms of what you want to do. Then the last thing I would say is don't feel super ... I know everybody's pressured to feel like they know exactly what they want to do and I understand that. I'm sure many of the people who are listening to this are very high performing, have always been very successful in life, have known exactly what they want to do. But there's a lot of benefit to maybe giving yourself the luxury of knowing you have a very long marathon ahead of you, as you think about the decision making in your career choices that you're going to make. If there's ever a time to be open to it, it's probably earlier in your career when you're maybe more willing to not only take some risks, but also be true to what you actually think will be interesting to you over a longterm career. Don't be afraid if it's not going to be a straight line. It might be a really curvy, cool path. At the time, it might feel a little discouraging, but don't be discouraged. Because I would argue, if I look back, some of my coolest decisions were the ones in which it wasn't this straight line, very clear path of what I wanted to do. But rather, I was either more open because of external circumstances or internal motivation to being a little bit more flexible and not so purposeful, and everything must be this in this timeframe. I think if you have some openness to that, it will really help you and probably put a lot less pressure on you as you're thinking about your career. Preena: Right. Yeah, that's really great advice. In terms of winding paths, switching over to your career and more of your day-to-day role, what would say is a challenge or challenges that you often find or encounter in your day-to-day role and how do you approach those? Natasha: That's a good question. My challenges in my day-to-day role. I'm fortunate in which I lead a functional team, so I have the benefit of having an amazing team that I work with every day across a variety of brands and products, across a very diverse portfolio. I've been lucky enough to do that at this current company, which is GE Healthcare, and the previous company I was at which is Abbott. Many times, if I think about the biggest challenges in my day-to-day, it really is around I would say three big areas. The first one is when you are such a large matrix company that is so dependent on your other functional teams, to ensure that you are all very clear on what the goal is, what you're all trying to accomplish, and that you're all rowing in the same direction, and have shared purpose and goals. Often times in our day-to-day, even in companies where you think everybody's on the same team, you can often find that there's actually sometimes a bit of misalignment or competing priorities. Sometimes that's because we're different functions or groups, sometimes it's because we're different segments. Sometimes it's just because we don't understand that shared goal. It's keeping everybody aligned to the mission, strategy, and vision. I would say as marketers actually, I feel like we are big drivers of that in an organization. It's something I always feel very responsible for and want to help my team feel very responsible for. That's the first one. The second one is we work in a very complex landscape. We're highly regulated here in healthcare. We want to do the right thing. Actually, I always tell people I'm so glad that we're highly regulated because the decisions we make actually impact life or death. It's actually for all the right reasons that we have very strict regulatory and approval processes, and then ongoing monitoring of all of our activities from our quality processes to our commercial processes and everything in between. But that can bring a lot of complexity. You've got to navigate a lot of sometimes tough legal and compliance discussions. But at the end of the day, the way we navigate them successfully as a team is really by reminding ourselves that the reason these regulations exist is to keep patients, our own family members who are consuming healthcare every day safe. We're able to do that. I feel we, despite sometimes difficult discussions, always get to the best answer in doing what's right for the patient and what's right for healthcare. Then the third thing, which is I think sometimes hard, is we all come to work every day because we actually care about healthcare and saving lives. That's sometimes really hard to remember when you get stuck in your day-to-day. You can be at a tough meeting, or a really hard strategy review, or a really hard finance review, or maybe you're missing your number in this sales goal. But at the end of the day, those hard days are really worth it because of what ultimately we're bringing to patients all over the globe. Again, there are these challenges, but over a long career I've been able to figure out how to successfully navigate them. So that I feel that even the challenges motivate me to come to work, and figure it out, and be better tomorrow. Better today and tomorrow than I was yesterday and in the past. I try to motivate my teams to think about that in the same way. Preena: Absolutely. Oh, yeah, that was very insightful. I think a lot of these can be applied to any fields, because a lot of times, in healthcare specifically, there is definitely life and death impacts. Then in other fields, people can have those same hard conversations and still need to have that resilience and build up that resilience to come back from that. Natasha: Very true. Very, very true. Probably very similar, just maybe different categories, but very similar discussions that would happen- Preena: Absolutely. Natasha: ... outside of healthcare, too. Preena: Yeah. Okay. Well, thank you very much for sharing this with us and thank you for joining us today. That is all the questions I have. We really value your time, and for coming on and speaking to all of our students. Thank you very much. Natasha: Thank you for having me. It was pleasure to talk to you.  

Host Justin Barnes recorded live at HIMSS25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week his guest is Simon Rost, Chief Marketing Officer at GE HealthCare. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Wine, flamingos, and a glass box…this is NOT your typical BILIH episode...Amit and Jeff join you from the ASRA Spring Annual Meeting 2025 in Orlando, Florida, where they recorded live interviews with over a dozen influential thinkers in regional anesthesiology. Join us as we chat and laugh with James Kim, Sandy Kopp and Nadia Hernandez over discussions of POCUS, probe covers, catheters, the NEW anticoagulation guidelines, and much much more!

Send us a textOn this ABM Done Right Podcast episode, Eric Gruber sits down with Jodie Lail (Revenue Marketing Leader at GE Healthcare) to discuss why teams need a revenue marketing organization if they are engaging in ABM. Eric also digs into the GE Healthcare ABM program and discusses what's working for them - and where there are opportunities to have a stronger revenue impact. 

In this episode, HR Daily Advisor Content Director Erika Randall catches up with the delightful Ben Eubanks, author and Chief Research Officer at Lighthouse Research & Advisory, at SPARK HR 2025 in Disney Springs. Eubanks' research includes surveying thousands of workers each year to understand the latest workplace trends. In this podcast, Randall and Eubanks have a lively chat about Eubanks' books, the workshops he led at SPARK, and how to help HR leaders solve workplace issues using “innovation sprints.” Eubanks' books include: Artificial Intelligence for HR: Use AI to Support and Develop a Successful Workforce Talent Scarcity: How to Hire and Retain a Shrinking Workforce Payroll Promise: Trust, Not Just Transactions Did you miss SPARK HR this spring? Not to worry! Join us live in San Antonio at SPARK TALENT 2025 and get practical strategies focusing on workforce planning, talent acquisition, and AI-driven processes! Discover proven solutions from top HR thought leaders from PepsiCo, Walmart, Staples, The Coca-Cola Company, Marriott, and GE HealthCare, and get ready to adapt your talent strategy for the future.

Send us a textBringing over a decade of experience in Leadership facilitation and coaching, driven by a passion for transformative learning experiences, Linmin (Michelle) Zhang, Founder and MD of IncluSmart, is widely recognized as an accomplished facilitator in DEI with specialized expertise in Strategic Planning, Culture Shaping, Action Planning, and Leadership Transformation. Her company, IncluSmart, inspired by the Chinese pictographic characters of 容锐, represents the idea that an inclusive environment evokes wisdom for both individuals and teams.With a background as a Global Product Manager in the Medical Equipment Industry at Mindray and GE Healthcare, Michelle leverages her 13 years of corporate experience to serve clients across various industries. Her portfolio spans across sectors and over 20 countries. Her unique approach combines facilitation, coaching, and drama-based role plays, enriching individual leadership development while fostering a sense of belonging among clients' employees. Her diverse skill set has enabled her to adapt her facilitation style to a variety of settings, including corporate meetings, government learning programs, and organizational development for NGOs.Michelle holds an MBA degree specializing in Strategic Planning for Leadership in Change Management, along with a medical degree specialized in Anesthesiology. A Certified Professional Facilitator, Michelle also serves on the Board of the International Association of Facilitators (IAF).[04:41s] From medicine to sales and marketing to facilitation [13:36s] Pivot into consulting and facilitating[30:38s] Discovering the world of IAF [39:09s] On the magic of facilitation #FacPower Connect with Michelle on LinkedInConnect with Vinay on X (formerly Twitter) and LinkedIn What did you think about this episode? What would you like to hear more about? Or simply, write in and say hello! podcast@c2cod.comSubscribe to us on your favorite platforms – Google Podcasts, Apple Podcasts, Spotify, Overcast, Tune In Alexa, Amazon Music, Pandora, TuneIn + Alexa, Stitcher, Jio Saavn and more.  This podcast is sponsored by C2C-OD, your Organizational Development consulting partner ‘Bringing People and Strategy Together'. Follow @c2cod on Twitter, LinkedIn, Instagram,

US equity futures are pointing to a higher open today. European markets are firmer, following notable strength in Asian markets. Global markets influenced by China Commerce Ministry's remark that Beijing is evaluating the US offer on trade negotiations, which signals China's openness to discussions. The softened tone now is being seen as a latest de-escalation signal following recent reports that Beijing has quietly exempted certain US-made goods from tariffs. Japan also aims to achieve a trade agreement with the US in June, though the country has suggested that treasury holdings are among cards it may use in talks.Companies mentioned: Viper Energy, GE HealthCare, Johnson & Johnson, Medtronic, JetBlue Airways

US President Trump said he is going to make a fair deal with China on trade; predicts that China will eat the tariffs.Stocks trade tentatively ahead of a slew of key risk events, including US GDP/PCE and earnings from Microsoft & Meta.USD looks to build on Tuesday's advances, EUR overlooks strong GDP, AUD is supported by hot CPI.USTs are contained into data & refunding, EGBs firmer but largely unaffected by a data deluge.Subdued trade across industrial commodities amid uncertainty and overall downbeat Chinese PMIs.Looking ahead, US ADP, GDP, PCE (Q1 & for March), ECI, BoC Minutes, Comments from BoE's Lombardelli, US Quarterly Refunding.Earnings from, Microsoft, Meta, Robinhood, Qualcomm, Albemarle, eBay, Humana, Caterpillar, International Paper, GE Healthcare, Hess.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

US President Trump said he is going to make a fair deal with China on trade; predicts that China will eat the tariffs.APAC stocks failed to sustain the positive handover from Wall St and traded mixed; Chinese official PMIs disappointed.European equity futures indicate a contained cash market open with Euro Stoxx 50 future flat after the cash market closed with losses of 0.2% on Tuesday.DXY is a touch higher and building on yesterday's slight gains, EUR/USD is back on a 1.13 handle, AUD leads post-CPI.Looking ahead, highlights include French GDP, German Import Prices, Retail Sales, Unemployment Rate, GDP, CPI, Italian GDP, CPI, EZ GDP, US ADP, GDP, PCE (Q1 & for March), ECI, BoC Minutes, BoE's Lombardelli, Supply from UK, Germany & US.Earnings from Microsoft, Meta, Robinhood, Qualcomm, Albemarle, eBay, Humana, Caterpillar, International Paper, GE Healthcare, Hess, Airbus, Credit Agricole, TotalEnergies, SocGen, UBS, DHL, Kion, Volkswagen, Mercedes Benz, Barclays, GSK, Segro & Glencore.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Die Nachrichtenlage ist auf der Ertragsseite gemischt bis negativ. Wir hören die oft gleiche Aussage: Das Umfeld ist extrem unsicher, mit einer schlechten Transparenz und Zeichen einer Abkühlung. Super Micro, Snap, First Solar, Norwegian Cruise und Booking Holdings gehören zu den Werten dieser Kategorie und tendieren schwächer. Die Aktien von Humana, GE Healthcare, Qorvo und Mondelez können sich nach den Zahlen und zumeist positiven Aussichten gut schlagen. Caterpillar tendiert freundlich, obwohl die Zölle im zweiten Quatal für $350 Mio. Gegenwind auf der Kostenseite führe werden. Neben den Ergebnissen stehen viele Wirtschaftsdaten im Fokus. Laut des Lohnabwicklers ADP wurden im April in der Privatwirtschaft weniger Jobs geschaffen, als man erwartet hatte. Das BIP ist im ersten Quartal um 0,3% geschrumpft. Die Wall Street rechnete mit 0,4% Wachstum. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

Die Nachrichtenlage ist auf der Ertragsseite gemischt bis negativ. Wir hören die oft gleiche Aussage: Das Umfeld ist extrem unsicher, mit einer schlechten Transparenz und Zeichen einer Abkühlung. Super Micro, Snap, First Solar, Norwegian Cruise und Booking Holdings gehören zu den Werten dieser Kategorie und tendieren schwächer. Die Aktien von Humana, GE Healthcare, Qorvo und Mondelez können sich nach den Zahlen und zumeist positiven Aussichten gut schlagen. Caterpillar tendiert freundlich, obwohl die Zölle im zweiten Quatal für $350 Mio. Gegenwind auf der Kostenseite führe werden. Neben den Ergebnissen stehen viele Wirtschaftsdaten im Fokus. Laut des Lohnabwicklers ADP wurden im April in der Privatwirtschaft weniger Jobs geschaffen, als man erwartet hatte. Das BIP ist im ersten Quartal um 0,3% geschrumpft. Die Wall Street rechnete mit 0,4% Wachstum. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ +++Probier Seeberger Snacks – deine natürliche Energiequelle. Mit dem Code wallstreet könnt ihr euch jetzt 20% Rabatt im Seeberger Onlineshop sichern: https://www.seeberger.de/?utm_campaign=podcast-q1&utm_medium=nativead&utm_source=podcast&utm_content=wallstreet +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

« Chiến đấu đến cùng » khi bị tấn công, « đáp trả tương xứng thuế đối ứng » của Mỹ và áp dụng đúng phương pháp của Washington để bảo vệ quyền lợi : Trung Quốc đã chọn giải pháp đối đầu trong cuộc chiến thuế quan với chính quyền Trump. Trong chưa đầy một tuần lễ, Trung Quốc chuyển từ « thế thủ » sang « thế công ». Trên nguyên tắc, kể từ 0 giờ ngày 10/04/2025 hàng Mỹ nhập khẩu vào Hoa Lục bị đánh thuế 34 % « tương tự » như hàng « made in China » bán sang Hoa Kỳ.Chỉ 48 giờ sau màn trình diễn của Donald Trump ở Nhà Trắng, mở màn một cuộc chiến thương mại với toàn cầu, tại Bắc Kinh bộ Thương Mại « đáp lễ » bằng hàng rào quan thuế. Trung Quốc cho mở điều tra nhắm vào hơn một chục doanh nghiệp Mỹ và hạn chế xuất khẩu 7 kim loại hiếm thiết yếu cho công nghệ cao và thiết bị điện tử trong dự án sản xuất chiến đấu cơ đời mới F-47 vừa được Washington rầm rộ loan báo.Sau một dịp nghỉ cuối tuần dài ngày, quay lại thủ đô Washington tổng thống Hoa Kỳ nổi đóa thấy Bắc Kinh chọn giải pháp đối đầu. Donald Trump chỉ trích Trung Quốc đi « nhầm đường » và đòi tăng thêm 50 % thuế hải quan nhắm vào hàng « made in China », bên cạnh mức thuế 54 % sắp bị áp dụng từ 0 giờ ngày 09/04, theo giờ của Washington. Lập tức Bắc Kinh khẳng định « trong tư thế sẵn sàng, quyết đấu đến cùng ».Trung Quốc « de-risking » với Mỹ Cơ quan tư vấn Capital Economics, trụ sở tại Luân Đôn đánh giá, lãnh đạo Trung Quốc nhận thấy rằng « kinh tế nước này đủ vững chắc để cưỡng lại mọi thủ đoạn của Donald Trump ».Bên cạnh những lập luận mang tính tuyên truyền, giới tài chính đồng loạt cho rằng, « Trung Quốc đã rút kinh nghiệm từ cuộc chiến thương mại lần trước với chính quyền Trump và có những bước chuẩn bị kỹ hơn ».Kế hoạch Made in China 2025 của chủ tịch Tập Cận Bình đã đem lại những kết quả cụ thể : Trung Quốc dẫn đầu một số lĩnh vực công nghệ mới, không chỉ là « công xưởng sản xuất hàng rẻ » mà đã trực tiếp cạnh tranh với các đối thủ ở Hoa Kỳ từ ô tô điện đến trí tuệ nhân tạo. Công cụ thông minh DeepSeek made in China đã khiến thế giới công nghệ ở Thung Lũng Silicon choáng váng.Trong lĩnh vực vệ tinh không gian, tháng 11/2024 Brazil đã ký hợp đồng với Qiafan, một công ty khởi nghiệp « vô danh » lấn sân của Elon Musk cung cấp các dịch vụ vệ tinh  Về công nghệ bán dẫn, Trung Quốc cũng không còn hoàn toàn lệ thuộc vào các nhà cung cấp phương Tây. Trong số các nhà sản xuất máy bay dân sự, Airbus của châu Âu và Boeing của Mỹ không còn trong thế độc quyền từ khi dòng Comac C919 của Trung Quốc bắt đầu xuất hiện… Một điểm khác nữa cho phép ông Tập Cận Bình tự tin lao vào cuộc đọ sức với Washington : Nhà cung cấp thiết bị viễn thông Hoa Vi vẫn tồn tại và thịnh vượng đó là trước các đòn trừng phạt liên tiếp của hai đời tổng thống Mỹ, Donald Trump và Joe Biden.Thị phần của Mỹ với Trung Quốc bị thu hẹpĐành rằng Trung Quốc vẫn là đối tác thương mại quan trọng thứ ba của Hoa Kỳ sau Mêhicô và Canada, nhưng nếu như hồi 2017, hơn 20 % kim ngạch xuất khẩu của Trung Quốc đổ về Mỹ, nay tỷ lệ  đó rơi xuống còn chưa đầy 15 % theo các số liệu của Hải Quan Trung Quốc được tuần báo Anh The Economist trích dẫn. Nói cách khác về xuất nhập khẩu Trung Quốc ít lệ thuộc hơn vào Mỹ so với 8 năm về trước.Báo Nhật Nikkei Asia trích lời bà Vương Đan, giám đốc công ty tư vấn Eurasia Group trụ sở tại Singapour, hồi 2017 « tổng kim ngạch xuất khẩu của Trung Quốc sang Hoa Kỳ chiếm khoảng 4 % GDP, nay tỷ lệ này chỉ còn là 3 % ».  Ngoài ra, để tiếp tục thâm nhập thị trường Mỹ, Bắc Kinh đã khai thác chiến lược « Trung Quốc +1 » qua một sô trung gian như Ấn Độ, hay Việt Nam và nhất là Mêhicô... Trong các khoản giao dịch hàng hóa Mỹ-Trung, cho đến hiện tại, Trung Quốc chủ yếu mua vào nông phẩm và năng lượng của Hoa Kỳ. Trước mắt, về dầu khí Bắc Kinh có thể trông cậy vào Nga. Về nông phẩm, ngũ cốc, Brazil và Achentina đã thu hẹp thị phần của các nông gia Hoa Kỳ, những thành phần cử tri ủng hộ Donald Trump.Đất hiếm, tiền tệ, công cụ pháp lý : những loại vũ khí trong tay Trung Quốc Kinh nghiệm từ « cuộc thương chiến lần thứ nhất » cũng do chính quyền Trump khởi động hồi 2018-2019 Trung Quốc đã tăng tốc chiến lược « tách rời khỏi » Hoa Kỳ cả về công nghệ lẫn thương mại. Và đó cũng là điểm khởi đầu cho phép nền kinh tế thứ hai toàn cầu không hề mặc cảm khi phải đương đầu với siêu cường số 1 thế giới. Do vậy Trung Quốc chuyển từ thế « thủ » sang thế tấn công ».Mỹ phụ thuộc vào đất hiếm để sản xuất các vật dụng kết nối, điện ô tô điện, vũ khí, vệ tinh... Do vậy, trong số các đòn đáp trả Donald Trump « Giải Phóng » Hoa Kỳ, Bắc Kinh đã loan báo thông báo « hạn chế » xuất khẩu 7 kim loại hiếm sang Mỹ.Một công cụ khác trong tay Bắc Kinh là phá giá đồng tiền quốc gia để hàng Trung Quốc xuất khẩu sang Mỹ vẫn hấp dẫn. Ngân Hàng Trung Ương đang hướng tới giải pháp này.Thế rồi Trung Quốc cũng dùng lá bài « an ninh quốc gia » để điều tra các tập đoàn Mỹ xuất khẩu một số mặt hàng « lưỡng dụng » sang Hoa Lục, cũng khai thác công cụ pháp lý « chống cạnh tranh bất bình đẳng » để trừng phạt các doanh nghiệp của Hoa Kỳ. Điều đó không cấm cản các giới chức Bắc Kinh vẫn khẳng định Trung Quốc là một « mảnh đất màu mỡ cho các nhà đầu tư quốc tế »Chiến tranh tâm lý Vào lúc tại Hoa Kỳ, giới đầu tư « nhốn nháo » vì chính sách thuế quan của Donald Trump, nhiều nhà tỷ phú hàng đầu (Bill Ackmann, Larry Fink ..), những người từng ủng hộ ông Trump trong cuộc tranh cử tổng thống 2024 kêu gọi Washington « dừng tay » thì thứ trưởng Thương Mại Trung Quốc tiếp đại diện nhiều tập đoàn Mỹ như của hãng xe Tesla hay tập đoàn bảo hiểm GE Healthcare…Ông Lăng Kích (Ling Jie) đưa ra thông điệp : Trung Quốc là « điểm đầu tư lý tưởng, an toàn và đầy hứa hẹn  với các tập đoàn nước ngoài, với các doanh nghiệp của Mỹ ». So với thời điểm hôm 20/01/2025, ngày ông tổng thống Trump nhậm chức, 180 tỷ đô la tài sản của ba doanh nhân Mỹ giàu nhất hành tinh đã tan thành mây khói. Cổ phiếu của tập đoàn Apple mất giá trong nhiều phiên giao dịch liên tiếp từ khi Nhà Trắng loan báo áp thuế 34 % hàng từ Trung Quốc nhập khẩu sang Hoa Kỳ, do 85 % các sản phẩm mang nhãn hiệu quả táo do nhân công Trung Quốc tạo ra để cung phục vụ các khách hàng Mỹ. Cũng chính vì biện pháp thuế sắp tới của tổng thống Trump mà dân Mỹ đua nhau sắm điện thoại thông minh trước khi giá mỗi chiếc iPhone trên thị trường đắt thêm từ 200 đến 300 đô la.Vỏ quýt dầy, móng tay nhọn Song bên cạnh những tuyên bố mạnh mẽ cả từ phía Bắc Kinh lẫn Washington, thực tế không thể chối cãi là tổng thống Mỹ đã mở một cuộc thương chiến với toàn cầu Trung Quốc là mục tiêu chính bị nhắm tới. Thiệt hại đầu tiên hết và nghiêm trọng nhất đè nặng lên hai nước liên quan. Nhà Trung Quốc học Valérie Niquet, thuộc Quỹ Nghiên Cứu Chiến Lược của Pháp nhấn mạnh đến điểm kẹt của Bắc Kinh trong cuộc đọ sức này :« Từ lâu nay ai cũng biết Trung Quốc bị thiệt hai nhiều trong cuộc đọ sức với Hoa Kỳ. Tập Cận Bình và những người tiền nhiệm đã đề ra mục tiêu điều chỉnh lại và lấy lại cân bằng trong mô hình phát triển, để cỗ máy sản xuất ít ngốn năng lượng hơn, để tiêu thụ nội địa là lực đẩy cho tăng trưởng của Trung Quốc. Nhưng từ đó đến nay, Bắc Kinh vẫn chưa thực hiện được mục tiêu này. Trung Quốc kỳ vọng bơt bị phụ thuộc vào xuất khẩu nhưng cho đến hiện tại thì xuất khẩu vẫn là đầu tàu kinh tế và Trung Quốc phụ thuộc nhiều hơn vào các thị trường nước ngoài, nhất là hai thị trường phát triển nhất là Mỹ và châu Âu. Nếu Hoa Kỳ đóng cửa thị trường, thì tác động đầu tiên đè năng lên người tiêu dùng ở Mỹ nhưng Trung Quốc cũng bị vạ lây »Nguy cơ bấn ổn nội địa Trung Quốc Cuộc chiến thương mại phiên bản 2 của ông Trump nổ ra vào lúc kinh tế Trung Quốc vẫn chưa phục hồi sau đại dịch COVID 19 và chưa thoát khỏi khủng hoảng địa ốc kéo dài. Valérie Niquet :« Chiến tranh kinh tế gia tăng cường độ giữa hai siêu cường thế giới này đã bắt đầu dẫn tới những hệ quả đối với toàn cầu chứ không chỉ giới hạn ở Hoa Kỳ và Trung Quốc. Bắc Kinh đã có các biện pháp trả đũa : áp thuế 34 % lên tất cả các mặt hàng Mỹ như đã loan báo. Tuy nhiên nếu chúng ta nhìn vào các sản phẩm của Trung Quốc bán sang Hoa Kỳ thì tổng cộng hàng Trung Quốc bị đánh thuế hải quan hơn 60 %. Không mấy khi tôi bênh vực cho Trung Quốc, nhưng phải công nhận rằng, mức thuế này là quá nặng và bị tung ra vào thời điểm bất lợi cho Trung Quốc. Kinh tế nước này đang đình đốn và từ nhiều năm qua, Trung Quốc vẫn chưa hoàn thành mục tiêu tăng tiêu thụ nội địa để bớt phụ thuộc vào xuất khẩu như vừa nói. Thành thử quyết định của Washington tuần trước, có nguy cơ gây bất ổn trong xã hội Trung Quốc và nguy cơ này là rất, rất lớn » .Tác động đối với Trung Quốc cũng sẽ mạnh hơn so với cuộc chiến thương mại hồi 2018-2019 do Hoa Kỳ cũng đã rút kinh nghiệm trong thương lượng với Bắc Kinh. Trong kế hoạch thuế quan lần này, châu Á là khu vực bị đánh nặng nhất. François Monnier, tổng biên tập tuần báo Investir chuyên về đầu tư :« Chúng ta thấy rõ mục tiêu của Donald Trump là để chuẩn bị cho một cuộc đối đầu với Trung Quốc. Chính vì thế mà Washington đánh thuế rất nặng vào các nước châu Á : Trung Quốc bị 34 % nhưng các nước châu Á khác cũng chịu mức thuế rất cao, tránh để Bắc Kinh sử dụng lại chiến lược Trung Quốc + 1, tức là di dời sản xuất sang các quốc gia chung quanh. Chúng ta thấy Việt Nam bị đánh thuế 46 %. Ở nhiệm kỳ đầu chính quyền Trump đã phạm phải sai lầm chỉ tập trung vào Trung Quốc và do vậy mà các doanh nghiệp nước này chuyển hướng đầu tư sang Việt Nam để từ Việt Nam, xuất khẩu sang Hoa Kỳ. Lần này chúng ta thấy Mỹ tấn công một cách toàn diện vào châu Á ». Ngày 30/03/2025 các quan chức cao cấp ba nước Trung Quốc, Hàn Quốc và Nhật Bản, ba nhà vô địch về xuất khẩu của châu Á họp tại Seoul và bàn về kế hoạch « hợp tác », hướng tới một « khu vực tự do mậu dịch » ba bên. Như thể dưới tác động của « trận bão » mang tên Trump, Tokyo, Bắc Kinh và Seoul tạm gạt sang một bên các bất đồng để cứu nguy kinh tế.Cũng dưới tác động của « Ngày Giải Phóng », Washington tạo cơ hội để Liên Hiệp Châu Âu và Trung Quốc tìm được một sân chơi chung. Thủ tướng Lý Cường và chủ tịch Ủy Ban Châu Âu, Ursula Von der Leyen trong cuộc điện đàm hôm 08/04 đã nhấn mạnh đến « trách nhiệm của Liên Âu tránh gây thêm căng thẳng thương mại toàn cầu ». Đây cũng có thể là cơ hội để làm sống lại thỏa thuận đầu tư mà Bruxelles và Bắc Kinh đã ký vội vào cuối 2020 nhưng từ đó đến này hoàn toàn bị lãng quên.  Sau cùng như báo The Economist nhận định chính sách thuế quan của ông Trump đẩy lạm phát ở Hoa Kỳ lên cao, dân Mỹ càng khó cai nghiện « hàng rẻ Trung Quốc »Nhưng Trung Quốc ý thức rằng, chiến tranh thương mại Washington khai mào có sức công phá rất lớn nếu như Donald Trump hủy hoại kinh tế Hoa Kỳ. Nền kinh tế số 1 thế giới bị đình đốn hay suy thoái thì sẽ là « một thảm họa » với hàng ngàn, hàng chục ngàn công ty Trung Quốc gia công cho các hãng của Mỹ. Các nhà xuất khẩu Trung Quốc cũng bị kéo vào vòng xoáy khủng hoảng vì cho đến nay chưa một thị trường nào trên thế giới, kể cả tại 27 nước Liên Âu có được sức mua mạnh như của 350 triệu dân Mỹ.

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch.  Das Buch zum Podcast? Jetzt lesen.  China revanchiert sich. Boeing, GE Healthcare, Apple, IPOs & Banken leiden. Adidas, Nike & Lululemon freut das Vietnam-Gespräch von Trump. Musk will keine Zölle. Hershey kauft Millionen-Popcorn, Microsoft feiert 50sten, Honda kann Space & Bitcoin ist stabil. Ein zyklisches Business in wirtschaftlich unsicheren Zeiten ist keine gute Kombo. Thyssenkrupp (WKN: 750000) steigt trotzdem. Der Grund: Rüstung, Infrastruktur und die Hoffnung auf Frieden. Von den 18 reichsten Menschen der Welt haben nur 2 dieses Jahr Rendite gemacht: Warren Buffett & Carlos Slim. Den ersten kennt ihr. Der zweite ist der John D. Rockefeller Mexikos mit América Móvil (WKN: A3D8PK), Grupo Carso (WKN: 885075) & Inbursa (WKN: 900573) Diesen Podcast vom 07.04.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com GE Healthcare is leading the way in global medical technology and pharmaceutical diagnostics by leveraging innovations like AI and cloud computing to reduce healthcare disparities and improve access. In this episode of The Beat Podcast, Dr. Taha Kass-Hout, GE Healthcare's Global Chief Science and Technology Officer, discusses how GE Healthcare is leading in global medical technology and pharmaceutical diagnostics through innovations like AI and cloud computing to reduce healthcare disparities and improve access. He introduces the AI-driven CareIntellect platform for oncology and the Health Companion project, which uses agentic AI to optimize patient treatment plans. Dr. Kass-Hout also explains how these technologies can alleviate clinician burnout by streamlining workflows and enhancing operational efficiencies, and highlights GE Healthcare's AI Lab initiative focused on mammography screening. Tune in to gain valuable insights into how GE Healthcare is driving innovation and transforming the future of healthcare. Resources: Connect with and follow Dr. Taha Kass-Hout on LinkedIn. Follow GE Healthcare on LinkedIn and visit their website. Fast Track Your Business Growth: Outcomes Rocket is a full-service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com

In this episode of the B2B Sales Trends Podcast, host Harry Kendlbacher sits down with Kelly Magnaudeix, VP of Sales at GE Healthcare, to unpack one of the most persistent challenges in sales leadership: why strong strategies often break down in execution. Kelly shares actionable insights on: - Building coherence between strategy and sales execution - Ensuring clarity and simplicity for frontline teams - Earning buyer trust through credibility and consistency - Navigating today's complex buying landscape - The top 3 (plus 1!) qualities of elite salespeople If you're a sales leader looking to close the gap between planning and performance, this episode is for you.

This week, we interviewed Laura Stoltenberg. Laura is the President and Chief Executive Officer at Cryosa. Laura brings nearly three decades of experience in strategy, business development, and global general management. She has a passion for developing and commercializing novel products to improve the standard of care. Most recently, Laura was Sector Chief Executive at Halma PLC, responsible for $1B in revenue. While at Medtronic, she served as Vice President and General Manager at Medtronic Diabetes and built a new business focused on Type 2 patients. Laura served as Chief Commercial Officer at Exact Sciences Corporation, where she was responsible for developing the global commercial strategy prior to FDA approval. Earlier in her career, she held escalating commercial and leadership roles at General Electric, including leading GE Healthcare's global bone densitometry business and completing a number of acquisitions. Laura earned an MBA at Columbia Business School and bachelor's degrees in electrical engineering and management at Bucknell University.

Are you ready optimize your team's performance and efficiency? In this podcast hosted by Mark Bailes, GE Healthcare Technical Product Lead Erica Ahn will be speaking on the art and science of organizational design. Drawing from her extensive experience at GE Healthcare, Erica shares insights on how to strategically structure teams, manage change, and drive business outcomes through thoughtful organizational approaches.

Meet Ron HockersmithRon grew up in Arizona and studied Mechanical Engineering at Arizona State University and The California Institute of Technology. After stints in gas turbine engine design and research on the mechanics of viruses he ended up in Milwaukee at GE Healthcare. Ron became a Lean Master Blackbelt and led teams in new product introductions at GE for 14 years before transitioning to a VP of Engineering role for an international defense contractor. Ron retired early in 2020 and after fixing everything there was to fix on his 1903 Victorian home, he got bored and started working part-time at a brewery before joining forces with former colleagues to start Amorphic Beer.Connect with Ron!Amorphic Beerhello@amorphicbeer.comLinkedInInstagramCheck out Manufacturing Happy Hour, hosted by Chris Luecke, the podcast where they get real about the latest trends and technologies impacting modern manufacturers.Highlights00:00 Welcome to Pints and Podcast01:06 Introductions and Cheers02:26 Discussing Beers and Brewing Techniques06:23 Meet Ron Hockersmith: From Engineering to Brewing07:46 Applying Manufacturing Principles to Brewing15:16 Challenges and Innovations in Craft Brewing22:37 Entrepreneurial Insights and Work-Life Balance27:48 I Just Learned That: Fun Facts and Insights35:47 Wrapping Up and Contact InformationConnect with the Broads!Connect with Lori on LinkedIn and visit www.keystoneclick.com for your strategic digital marketing needs! Connect with Kris on LinkedIn and visit www.genalpha.com for OEM and aftermarket digital solutions!Connect with Erin on LinkedIn!

In this special live episode, with guests Lisa Christensen, Hillary Miller and Christopher Lind, we explore their experience and deep expertise on the topics of L&D strategy and team structures - and it’s a masterclass of a conversation. Register for L&D Next 3rd - 6th March for free today at https://360learning.com/l-and-d-next/2025/ KEY TAKEAWAYS Understand what L&D is there to achieve. Team structures have to evolve and be flexible. L&D structure has to be right for achieving L&D aims, so it may be different from other teams in the organisation. Build adaptable teams by focusing on skillsets. Leverage data and hone in on one KPI. Understand which relationships and functions you need to focus on. That will evolve. Work holistically with other areas of the business. BEST MOMENTS “I've never seen a truly centralized model, ever.” “We can get hung up on the hierarchy of things and miss out.” “You gotta know who your players are, their bench strengths.” “We need better data capabilities in learning.” “Figure out what they care about and then lean on that.” Lisa Christensen Lisa leads McKinsey & Company's Learning Design and Development Center of Excellence, a global team of design experts, designing and building the learning that develops McKinsey Partners and professionals, enabling them to deliver incredible client impact. Lisa founded and leads McKinsey's Learning Research and Innovation Lab and sits on the global learning leadership team. https://www.linkedin.com/in/lisachristensen Christopher Lind Christopher Lind is a dynamic leader at the intersection of business, technology, and human experience, serving as an executive advisor, AI ethicist and sought-after voice in the L&D space. As a former Chief Learning Officer for ChenMed and GE Healthcare, Christopher has led transformative learning strategies that enhance workforce capability and business performance. A prominent commentator, speaker, and thought leader, he is known for his forward-thinking approach to digital learning, AI, and the evolving role of technology in talent development. https://www.linkedin.com/in/christopherlind Future Focused: https://christopherlind.substack.com Hillary Miller Hillary Miller is a seasoned Learning & Development leader currently heading L&D at HCA Healthcare. With a passion for driving workforce capability and business impact, she brings extensive experience in healthcare education and leadership development. Previously, as Chief Learning Officer at Penn State Health, Hillary led enterprise-wide learning strategies, fostering a culture of continuous development and innovation. https://www.linkedin.com/in/hillarybmiller VALUABLE RESOURCES https://podcasts.apple.com/gb/podcast/the-learning-development-podcast/id1466927523 L&D Master Class Series: https://360learning.com/blog/l-and-d-masterclass-home THE HOST David James David has been a People Development professional for more than 20 years, most notably as Director of Talent, Learning & OD for The Walt Disney Company across Europe, the Middle East & Africa. As well as being the Chief Learning Officer at 360Learning, David is a prominent writer and speaker on topics around modern and digital L&D. CONTACT METHOD Twitter:  https://twitter.com/davidinlearning LinkedIn: https://www.linkedin.com/in/davidjameslinkedin L&D Collective: https://360learning.com/the-l-and-d-collective Blog: https://360learning.com/blog L&D Master Class Series: https://360learning.com/blog/l-and-d-masterclass-home

APAC stocks traded somewhat mixed albeit with a mostly positive bias among the major indices following the two-way price action across global markets owing to hot US CPI data and geopolitical optimism.US President Trump posted on Truth that he had a lengthy and highly productive phone call with Russian President Putin, and they agreed to have their respective teams start negotiations immediately. Trump then said he spoke to Ukrainian President Zelensky and the conversation went very well.US President Trump did not sign reciprocal tariffs order on Wednesday after stating that he may, while the White House schedule showed President Trump is to sign executive orders on Thursday at 13:00EST/18:00GMT.Fed Chair Powell offered a note of caution on the latest CPI reading and said the Fed targets PCE inflation, which is a better measure, and stated they will know what PCE readings are late on Thursday after the PPI data.European equity futures indicate a higher cash market open with Euro Stoxx 50 futures up by 1.1% after the cash market closed with gains of 0.3% on Wednesday.Looking ahead, highlights include German Final CPI, UK GDP Estimate and Services, Swiss CPI, US Jobless Claims, PPI, IEA OMR, Supply from Italy & US, Comments from ECB's Cipollone.Earnings from Datadog, Baxter, Deere, Duke Energy, GE Healthcare, PG&E, Coinbase, Draftkings, Applied Materials, Airbnb, Palo Alto, Roku, Wynn, Siemens, Delivery Hero, Commerzbank, Nestle, Orange, British American Tobacco, Unilever, Barclays & Moncler.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

US President Trump did not sign reciprocal tariffs order on Wednesday after stating that he may, while the White House schedule showed President Trump is to sign executive orders on Thursday at 13:00EST/18:00GMT.Stocks mostly firmer on constructive geopolitical updates; US futures are mixed ahead of PPI.USD softer as markets weigh potential Ukraine peace deal and lack of reciprocal tariffs (so far).Bonds attempt to recoup CPI-driven losses into PPI though geopols is capping.Crude continues the Russia/Ukraine downside seen in the prior session; reports suggested Israel/Hamas had come to an understanding, but this was subsequently denied by Israeli PM Netanyahu's Office.Looking ahead, US Jobless Claims, PPI, Supply from the US. Earnings from Datadog, Baxter, Deere, Duke Energy, GE Healthcare, PG&E, Coinbase, Draftkings, Applied Materials, Airbnb, Palo Alto, Roku, Wynn.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Join Michelle Martin on her tour of markets! DBS posts record earnings and announces new dividends - what does this mean for investors? CapitaLand Ascott Trust, CapitaLand India Trust, and Mapletree Logistics Trust see director buy-ins, while Suntec REIT’s takeover bid fails. In global markets, activist investor Elliott builds a stake in BP, while BYD surges on smart-driving tech. Apple faces UK government scrutiny, and Bank of America sees Warren Buffett’s possible exit. Plus, a preview of earnings from McDonald’s, Coca-Cola, and more.See omnystudio.com/listener for privacy information.

Discover how AI is revolutionizing hospital operations with Bree Bush, GM of Command Center at GE Healthcare. In this eye-opening episode, Bree shares her journey from mechanical engineer to healthcare innovator, revealing how GE's AI-driven command centers are transforming patient care and hospital efficiency. Key takeaways:  Learn about GE's groundbreaking command center technology and […]

In this episode of Medsider Radio, we sat down with Brent Ness, President and CEO of Aclarion, a startup developing a decision-support tool designed to improve the diagnosis and treatment of chronic low back pain. Brent has over 28 years of experience in medtech. Before Aclarion, he led Cleerly as President & CCO, driving the adoption of their AI cardiology solution through strategic partnerships. As COO of Mighty Oak Medical, he guided their FIREFLY spine navigation platform from FDA clearance to international launch. At HeartFlow, Brent spearheaded the global expansion of their image-based SaaS solution, and at Medtronic, he led the acquisition and rollout of the O-Arm technology. His career also includes leadership roles at GE Healthcare, Philips North America, and ProNerve.In this interview, Brent shares his approach to reimbursement, why continuing to prove your technology is crucial (even after regulatory approval), and how to effectively engage with KOLs for optimal support.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Brent Ness. 

Healthcare facilities face significant challenges in procuring and managing medical imaging equipment. These high-cost, high-stakes purchases, such as MRI and CT scanners, can directly impact patient care and financial sustainability. With declining reimbursements and increasingly complex technologies, the importance of expert guidance in making these decisions has never been greater. In fact, in 2022, U.S. hospitals spent an estimated $4.29 billion on service-related expenses for diagnostic imaging equipment, marking a 13.3% increase since 2020.How can smaller hospitals and healthcare facilities, with limited resources and expertise, navigate these critical decisions to ensure they receive optimal value and service?This episode of I Don't Care with Dr. Kevin Stevenson dives into these pressing questions with Scott Finkelmeyer, founder of Key Imaging Partners LLC. Together, they discuss the challenges and strategies healthcare providers face when procuring medical imaging equipment, from negotiating contracts to embracing new technologies like AI.Highlights from the Episode:Expert Guidance on High-Stakes Decisions: Finkelmeyer shares strategies for navigating vendor negotiations, emphasizing the importance of detailed contract reviews and ensuring optimal value for medical imaging equipment purchases.The Role of AI in Radiology: AI technology is transforming radiology by enhancing efficiency and doubling imaging capacity, helping facilities avoid costly equipment expansions.Leadership and Mentorship: Scott reflects on the importance of strong leadership and mentorship in empowering teams and improving procurement outcomes.Scott Finkelmeyer is the CEO of Key Imaging Partners, LLC, leveraging over 25 years of experience with top diagnostic imaging manufacturers to assist healthcare providers in optimizing medical imaging technology and service strategies. He previously held leadership roles at Siemens Healthineers and GE Healthcare, where he excelled in strategic sales and account management. His expertise lies in helping healthcare providers optimize imaging technology acquisitions and service agreements. Through his company, Scott helps clients save time and money while increasing purchasing confidence in a rapidly evolving healthcare landscape.

Healthcare facilities face significant challenges in procuring and managing medical imaging equipment. These high-cost, high-stakes purchases, such as MRI and CT scanners, can directly impact patient care and financial sustainability. With declining reimbursements and increasingly complex technologies, the importance of expert guidance in making these decisions has never been greater. In fact, in 2022, U.S. hospitals spent an estimated $4.29 billion on service-related expenses for diagnostic imaging equipment, marking a 13.3% increase since 2020.How can smaller hospitals and healthcare facilities, with limited resources and expertise, navigate these critical decisions to ensure they receive optimal value and service?This episode of I Don't Care with Dr. Kevin Stevenson dives into these pressing questions with Scott Finkelmeyer, founder of Key Imaging Partners LLC. Together, they discuss the challenges and strategies healthcare providers face when procuring medical imaging equipment, from negotiating contracts to embracing new technologies like AI.Highlights from the Episode:Expert Guidance on High-Stakes Decisions: Finkelmeyer shares strategies for navigating vendor negotiations, emphasizing the importance of detailed contract reviews and ensuring optimal value for medical imaging equipment purchases.The Role of AI in Radiology: AI technology is transforming radiology by enhancing efficiency and doubling imaging capacity, helping facilities avoid costly equipment expansions.Leadership and Mentorship: Scott reflects on the importance of strong leadership and mentorship in empowering teams and improving procurement outcomes.Scott Finkelmeyer is the CEO of Key Imaging Partners, LLC, leveraging over 25 years of experience with top diagnostic imaging manufacturers to assist healthcare providers in optimizing medical imaging technology and service strategies. He previously held leadership roles at Siemens Healthineers and GE Healthcare, where he excelled in strategic sales and account management. His expertise lies in helping healthcare providers optimize imaging technology acquisitions and service agreements. Through his company, Scott helps clients save time and money while increasing purchasing confidence in a rapidly evolving healthcare landscape.

Welcome back to The Private Equity Podcast by Raw Selection, hosted by Alex Rawlings. Today's guest is Richard Neff, a proven operator and operating partner with decades of experience in private equity and a 25-year career at GE Capital and GE Healthcare. In this episode, Richard shares insights into the investor-operator relationship, the importance of infrastructure, and lessons learned from GE's legendary playbook for growth and transformation.Breakdown; [00:00] Reflecting on 2024 and looking ahead to 2025.[00:28] Introduction to Richard Neff: His background in healthcare, tech-enabled services, industrial services, and 25 years at GE.[00:57] One common private equity mistake: Over-ambitious plans versus focused execution.[02:17] What typically moves the needle in $20M revenue businesses: Human capital and growth initiatives.[03:38] Key areas private equity firms can better align with portfolio executives.[04:36] The gap between evaluators (investors) and doers (operators): Surprises post-acquisition.[06:29] The infrastructure gaps often missed: Sales team depth, product development, and capability issues.[07:53] Why infrastructure and capability investment is underestimated and often delayed.[09:21] Richard's experience at GE Capital: A private equity-style approach to business building.[10:49] How GE executed a structured playbook for M&A, growth, and cultural integration.[11:45] Lessons from managing hyper-growth businesses pre- and post-financial crisis.[12:44] Richard's key takeaways from GE:The value of a structured 100-day plan.Building global networks and talent development.Creating a sense of belonging and shared purpose.[14:36] Applying GE's lessons to smaller portfolio companies: Building camaraderie and engagement.[15:35] The power of networking within private equity portfolio companies.[16:58] Why private equity firms often miss the value of connecting their C-suite leaders.[18:26] Richard's influences: His diverse reading list including Fast Company, Wired, and Financial Times.[19:47] Encouraging problem-solving and situational adaptability through varied experiences.[20:13] How to contact Richard Neff. To be added to the book waitlist, you can email alex.offer@raw-selection.comThank you for tuning in! Connect with Richard on LinkedIn here. To get the newest Private Equity episodes, you can subscribe on iTunes or Spotify here.Lastly, if you have any feedback on the podcast or want to reach out to Alex with any questions, send an email to alex.rawlings@raw-selection.com

Welcome to The Golden Age of Orthodontics, the podcast that keeps orthodontists ahead of the curve in innovation and patient care. In today's episode, hosts Dr. Leon Klempner and Amy Epstein are joined by Jose Hogan, President and CEO of Align Technology They delve into how Align is reshaping the future of orthodontics with breakthrough technologies and digital solutions. Joe shares insights on how orthodontists can embrace the digital shift, addressing the challenges and benefits of transitioning to digital workflows. From AI and 3D printing advancements to reducing treatment times and minimizing office visits, this conversation looks into the transformative power of digital orthodontics and Align's ongoing commitment to supporting orthodontic practices worldwide. Tune in to learn how these innovations reshape patient care and practice efficiency in the orthodontic industry. Remember, there has never been a better time to be an orthodontist.IN THIS EPISODE: [4:40] Joe Hogan explains how Align Technology supports orthodontists[10:24] Joe predicts digital trends and advancements for 2025[14:20] Joe is hopeful that a stronger economy will be favorable to orthodontists[18:47] Joe addresses concerns from the orthodontist community[25:09] Why are so many orthodontists still using brackets and wires rather than Aligner TherapyKEY TAKEAWAYS: Under Joe Hogan's leadership, Align Technology invests over $350 million annually in digital orthodontics, focusing on groundbreaking tools like ClinCheck and 3D controls tailored for orthodontists. Despite serving general dentists, Align Technology remains committed to innovation and partnerships within the orthodontic community.Joe Hogan highlights three innovations shaping orthodontics: the iTero Lumina scanner for faster, precise imaging, the five-minute ClinCheck for touchless digital workflows, and 3D printing as a breakthrough in aligner manufacturing. These advancements set Align Technology apart, focusing on groundbreaking platforms rather than incremental changes.Despite aligners handling 95-100% of orthodontic cases, widespread adoption could be improved by the workflow transformation required for digital integration. Joe Hogan highlights the efficiency gains of aligners—reduced treatment time, fewer visits, and scalability—while acknowledging the challenges for orthodontists in retraining staff and adapting to a digital-first approach. This shift demands commitment from practitioners.RESOURCE LINKSPeople + Practice - Website Leon - EmailAmy - EmailPeople + Practice - EmailAlign Technology - WebsiteBIOGRAPHY: Joseph Hogan, President and CEO of Align Technology, has led the company to significant financial success over the past eight years. With extensive leadership experience from ABB and GE Healthcare, where he increased revenues by 25% and doubled them from $7 billion to $16 billion, Hogan brings a wealth of expertise in business strategy, market development, and operational management.

Step inside the fascinating world of AI-powered healthcare transformation! 

Dr. Linda Chu is joined by Dr. Matthew Covington and Dr. Regina Rosenthal to discuss the challenges in diagnosing and treating invasive lobular carcinoma (ILC) of the breast. They explore imaging difficulties, unique metastatic patterns, and strategies for improving detection and patient care. Sponsored by GE HealthCare.

This podcast is brought to you by GE HealthCare, an SNMMI Value Initiative member. This podcast asks about AI's promise in nuclear medicine in image acquisition, image reconstruction, post processing, computer diagnosis has been promising, but clinical adoption will require AI to provide a higher value compared to the standard of care. This podcast will ask question such as how can AI provide this improved bio nuclear medicine? What are some of the strategies that can help us with AI demonstrating clinical value? What are some of the initiatives that we can take as a society and as a community to strengthen this value, and how can we rally the community to take steps towards strengthening this value? 

In this episode of Medsider Radio, we sat down with Cary Vance, CEO of PhotoniCare. The company's FDA-cleared OtoSight™ Middle Ear Scope is a clinical diagnostic tool that offers a non-invasive and comprehensive assessment of middle ear fluid. Cary is a proven medtech leader with over two decades of experience across large strategics like GE Healthcare and Covidien, and nearly 11 years as CEO of six different startups, including Titan Medical and Hansen Medical where he drove commercialization, fundraising, and M&A opportunities. He's been the Chairman, President, and CEO of PhotoniCare since May 2023.In this interview, Cary shares why clinical evidence, workflow efficiency, and financial viability are the three pillars of medtech success and how he prepares for launches and M&As from day one.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ lifescience investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Cary Vance. 

Jasmina (Jass) Brooks is President, Electrophysiology, Johnson & Johnson MedTech (formerly Biosense Webster, Inc.), a global leader in the science, diagnosis and treatment of heart rhythm disorders. Jass is a seasoned leader with more than 25 years of experience in the cardiovascular field, primarily focused on electrophysiology. She has accountability for setting the J&J MedTech Electrophysiology end-to-end global strategy as a leader in cardiac ablation, advancing its innovation agenda, and driving execution to position the organization for continued growth. Previously, Jass was Vice President, Global Strategic Marketing, Biosense Webster, Inc. In this role, she worked with cross-functional and international teams to set the strategy and shape the company product pipeline to drive growth, market share, and profitability. Having joined Biosense Webster in 2014, Jass held positions of increasing scope and responsibility in the Global Strategic Marketing Organization. Prior to joining Johnson & Johnson, Jass spent 15 years at GE Healthcare, where she held various roles in commercial marketing, global strategic marketing, product development and engineering in the US and EMEA. She holds a Bachelor of Science in Biomedical Engineering from Louisiana Tech University. Jass has dedicated her career to championing excellence in patient outcomes and solving unmet medical needs. She is a collaborative leader with a deep knowledge of the electrophysiology space, a track record of successfully driving growth and market leadership, as well as a deep commitment to developing talent and fostering a culture of collaboration and inclusivity. In 2023, Jass was named as one of LA Times' Healthcare Visionaries. In 2024, she was honored as one of Orange County Business Journal's Women in STEM and was also celebrated as one of the publications 2024 “OC 500,” an annual Directory of Influence that honors the most impactful leaders, innovators, and changemakers in the OC business community. -- Critical Mass Business Talk Show is Orange County, CA's longest-running business talk show, focused on offering value and insight to middle-market business leaders in the OC and beyond. Hosted by Ric Franzi, business partner at REF Orange County.

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi unpacks the career of Tesh Elavia, vice president of research and development at BD's surgery division. Elavia's parents strongly encouraged him to leave his home in India to study in the states. Listeners will hear how he built that uncertain start into a stellar MedTech career. This episode is sponsored by FPT. Learn more about the company in the podcast or visit FPTsoftware.com MassDevice Editor Chris Newmarker kicks this off with the Newmarker's Newsmakers - Edwards Lifesciences, GE Healthcare, Movano Health, Boston Scientific and layoffs in the MedTech Industry. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

About Dr. Taha Kass-Hout:Dr. Taha Kass-Hout is the Global Chief Science and Technology Officer at GE Healthcare, where he drives advancements in AI-based medical imaging and diagnostics. With a background in interventional cardiology and machine learning, he previously served as Vice President of Machine Learning and Chief Medical Officer at Amazon, leading pivotal health tech projects like Amazon HealthLake and Amazon Comprehend Medical1. Dr. Kass-Hout also held key roles in the Obama Administration, including the FDA's first Chief Health Informatics Officer and Director of Information Science and Informatics at the CDC. His work focuses on leveraging AI and cloud computing to improve global healthcare access and reduce disparities.Things You'll Learn:AI and cloud computing are being used to reduce global healthcare disparities and improve patient care.CareIntellect is an AI-driven platform for oncology that simplifies access to complex data and expedites patient care processes.The Health Companion project employs agentic AI to optimize patient treatment plans and alleviate clinician burnout.Technological advancements are streamlining workflows and enhancing operational efficiencies.Resources:Connect with and follow Dr. Taha Kass-Hout on LinkedIn.Follow GE Healthcare on LinkedIn and visit their website.

In this episode of DeviceTalks Weekly, Host Tom Salemi interviews Kit Yee Au-Yeung, general manager of AQMed at SandBoxAQ, an Alphabet spinout using AI and sensors to develop new tools in several industries. Sandbox's medical group is using these new technologies to develop advanced AI-powered magnetocardiography (MCG) technology to improve cardiac diagnostics. MassDevice's Chris Newmarker also returns with his Newmarker's Newsmakers including - Dr. Mehmet Oz, CMS, Supira, GE Healthcare and Medtronic. This episode is sponsored by DeviceTalks Boston. Thank you for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

 In this episode, Sandy Vance interviews Parminder “Parry” Bhatia, Chief AI Officer at GE Healthcare, about the integration of generative AI and machine learning in healthcare. They discuss the transformative potential of these technologies in improving clinical efficiency, reducing burnout, and enhancing patient care. Parminder shares insights on recent innovations, the concept of agentic AI, and the importance of responsible AI practices in ensuring safe and effective healthcare solutions. The discussion highlights GE Healthcare's commitment to advancing AI technologies while maintaining a focus on ethical considerations and collaboration with clinical partners.In this Episode they discuss:GE Healthcare is leading in AI and machine learning integration.Generative AI is set to revolutionize healthcare data management.AI technologies can significantly reduce clinical burnout.The Care Intellect application enhances oncology care efficiency.Agentic AI offers proactive solutions in complex healthcare scenarios.Responsible AI practices are crucial for building trust in technology.AI can streamline workflows and improve patient experiences.Collaboration with clinical partners is essential for innovation.The AI Innovation Lab fosters early-stage research and development.GE Healthcare aims to enhance healthcare delivery for over a billion patients.About Parminder "Parry" Bhatia: At GE HealthCare, Parminder is focused on integrating AI across areas including smart devices, across the patient journey, and at the hospital operation level.GE HealthCare has a long track record innovating in AI, and has topped the Food and Drug Administration's (FDA) list of AI-enabled medica devices for three years in a row, with 80+ AI-enabled medical device authorizations. Parminder leads a team that is helping to advance AI integration within medical devices at GE HealthCare, with the ultimate goal of enhancing patient outcomes and creating a world where healthcare has no limits. Parry is part of the company's internal committee on responsible AI to help ensure that new AI applications are reliable, scalable, and ethically sound. He has been recognized by the AIM “AI 100” 2024 Awards and Constellation Research's Artificial Intelligence 150 “AI 150” list.Previously, Parminder was Head of Science for Generative AI at Amazon, where he led the development of machine learning and generative AI products including Amazon Comprehend Medical for analyzing medical record data at scale, Amazon Q for developer productivity, and Amazon Bedrock for democratizing access to Large Language Model technologies globally.He has held previous roles in AI and machine learning at Microsoft and Georgia Tech.

In the latest edition of the Design Brief, we sit down with Jay Hill, the Vice President of Advanced Technology at GE Healthcare, to discuss the company's approach to product development in the complex healthcare technology space.   Jay offers insights into:   GE Healthcare's deep engagement with clinicians at all stages of product development, from needs identification to prototype evaluation.   The "lead program integrator" role and its importance in managing the integration of complex, multi-disciplinary healthcare systems.   GE Healthcare's structured approach to monitoring technology trends and matching them with clinical problems to inform their product roadmap.   Exciting applications of AI in healthcare, from automating workflows to supporting clinicians in making better diagnostic and treatment decisions.   Advice for medical students and early-career clinicians on embracing the evolving relationship between their practice and advancing technologies. 

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Marwan Berrada, founder and managing partner of Santa Clara-based T45 Labs about how incubators can start new companies at a time when early-stage funding is scarce. MassDevice Editor Chris Newmarker deliveres his Newmarker's Newsmakers including GE HealthCare, Zimmer Biomet, Momentis Surgical, Johnson & Johnson MedTech and, of course, the news surrounding HHS. This episode is sponsored by DeviceTalks Boston. Register at Boston.DeviceTalks.com. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

In this industry sponsored episode, Host Praveen Ranganath is joined by familiar esteemed guests Dr. Waseem Cossor and Dr. Madhu Ganigara to discuss the formation and growth of their academic pediatric cardiac CT program in Chicago.This episode is sponsored by GE HealthCare.References to a specific product, process, or service by speakers in this podcast episode do not constitute or imply an endorsement by the Society of Cardiovascular Computed Tomography. The views and opinions expressed in do not necessarily reflect those of the Society of Cardiovascular Computed Tomography. 

Major changes to the Dow Jones you should know about! The Dow Jones has changed again as Nvidia (NVDA) replaced Intel (INTC) and Sherwin-Williams (SHW) replaced Dow Inc. (DOW). The most recent change in the Dow Jones came on February 26th when Amazon (AMZN) replaced Walgreens (WBA). With the addition of Nvidia, much of the Mag Seven will now be present in the Dow Jones. As I mentioned Amazon was recently added, but Apple and Microsoft have been components for many years. It seems the Dow has really lost relevance as it has trailed the S&P 500 and Nasdaq in popularity and performance. I worry adding NVDA at this point in time could be buying high and at times the committee has had poorly timed decisions. Back in August 2020 the committee ended up doing a three-company swap as they eliminated Exxon, Pfizer, and Raytheon and added Amgen, Honeywell, and Salesforce. The interesting swap was Exxon (XOM) for Salesforce (CRM) considering XOM is up close to 200% not including dividends during that time period while CRM is up just around 10% during the same timeframe. Another poor decision came back in June 2018 when the committee swapped General Electric (GE) for Walgreens (WBA). Since the switch GE is up over 180% and I don't believe that return even includes the benefit of the spinoffs GE Vernova and GE Healthcare, which would make the return even more attractive. During the same timeframe, Walgreens has had a rough time and the stock has actually fallen over 80%. While some maybe excited about the move, I wouldn't be surprised if Intel actually outperformed Nvidia over the next 5 years.    The election is over, what investors should do now! My belief is that your plan should not have a drastic change after the Trump win, but there may be small changes to keep an eye on. The first thing I would tell people is to be careful chasing proposed winners or selling potential losers this early in the game. Ultimately, we don't know exactly what policy changes he will be able to implement and we don't even know at this point who will fill his cabinet. I was bullish on financials before the Trump win, but now that he will be entering office the group will likely benefit from a more relaxed regulatory environment compared to the current administration. Regional banks in particular look like they could be big beneficiaries, but be careful as many already had a big first day move after the election results. I was somewhat surprised to see big tech as a big winner as well, but it seems in today's world everything is good for big tech. If you have been following us, you know we are skeptical of many of these big tech companies due to excessive valuations and frankly I just don't see how a Trump presidency would be overly positive for the group. Especially considering both Trump and VP elect JD Vance have been critical of the group in the past. I would not be surprised to see continued regulatory pressure for some of these companies even after the change in the White House. Health care is also an interesting sector with Robert F. Kennedy Jr. being a large part of the Trump campaign considering his criticisms of vaccines and the food system. While this is something to keep your eye on, I don't believe the group is completely doomed and in fact you could find some opportunities if stock prices continue to be pressured. Green energy is also in the cross hairs and many of these companies saw large declines after the results. While this may be an area of concern if the Inflation Reduction Act is repealed, I believe investors may be able to find some good opportunities if these businesses can maintain profits especially considering our need for more energy. At this point in time, I would wait for more clarity on that space as changes to tax credits could totally disrupt the current earnings picture for many of these businesses. Overall, you may be excited or disappointed with the results, but ultimately the strategy of investing in good quality companies at fair prices over the long term should not change!   Do you think you will be able to retire when the time comes? At Wilsey Asset Management we continue to work very hard to encourage people to invest for retirement and also to invest wisely so they can retire at a reasonable age. What is a reasonable age? Most would say 65 but in recent surveys the average age is 62, that's a surprise to me. What is also a surprise is that in 2002 the average age of retirement was 59, and in 1991 it was 57. Could it be because people are living longer and are getting bored in retirement for 20 years or longer? I'm not sure of the reason why but it seems like we have to work a little bit harder based on a survey from New York Life that says 22% of retirees think they may never be able to retire. I have often said getting old is not that great but getting old and not having a good investment portfolio, well that can be devastating. Be sure you are taking advantage of workplace retirement plans, IRAs, or even investing in a tax advantaged brokerage account.   Is Your Social Security Taxable? Social Security benefits are taxable, but they are not treated like any other source of income. Currently there are only 9 states that tax Social Security: Colorado, Connecticut, Minnesota, Montana, New Mexico, Rhode Island, Utah, Vermont, and West Virginia. The remaining states do not tax it so the majority of Americans do not need to report it on their state returns. Since this income does not take up any room in state tax brackets, it is much easier to keep taxable income lower in retirement at the state level. On the federal level, between 0% and 85% of Social Security benefits is reportable as income, so at least 15% is tax free. The lower someone's income is in retirement, the greater chance that a larger portion of their Social Security will be tax free. The ratio of taxable to non-taxable benefits is based on “combined” income which is a Social Security Administration term that includes ½ of Social Security benefits plus all remaining income sources. If a married couple's combined income is less than $32,000, none of their benefits are taxable. If combined income is between $32,000 and $44,000, up to 50% of benefits are taxable, and if combined income is greater than $44,000 then up to 85% of benefits are taxable. If these parameters seem low, that is because they were created in 1983 and have not been indexed for inflation. In the 80's, $32,000 and $44,000 was a relatively high level of retirement income so most people did not have to pay taxes on it. Over the last 4 decades as income levels have naturally risen due to inflation, more and more recipients are forced to pay taxes on their benefits. It is unfortunate that Social Security is taxable at all because it used to be tax free prior to 1983. Now we are taxed in retirement when we receive it, and we are taxed on the income we earn that is used to pay into Social Security while we are working resulting in double taxation. It is possible to structure retirement income in a way that reduces the taxation on Social Security, but it is getting increasingly harder to do so.   Companies Discussed: First Solar, Inc. (FSLR), Five Below, Inc. (FIVE) & Sherwin-Williams Company (SHW)

Is your image telling your story as intended? How to look better and real on camera Episode 228 (Maia is based in Chicago) In this conversation with Maia Rosenfeld we explore: How do other judge you based on your photograph? How a photographer first needs to understand you How to stop sabotaging your photographs What a better word than "cheese" The power of visual messages on trust The first impression when we see your photo on Linkedin How might the photograph convey your brand? Why do people check their reflection when they walk by store windows About our guest, Maia Rosenfeld: Maia has been a headshot photographer in Chicago, Los Angeles and New York for 28 years. Some of her corporate clients include BMW, J.P. Morgan Chase, Salesforce, GE Healthcare and The Make-A-Wish Foundation. She's never met a stranger. Learn more about her photography services at MRPCreative.com ----- Excerpts from this conversation with Maia Rosenfeld: Is it welcoming? Do you look smart? Do you look like you're good at what you do? Do you look like someone they want to spend the time reading the next little blurb that's probably only three sentences underneath their chin, getting to figure out what is the unique thing, the differentiator of each client that comes into my studio to figure out how to tell their story, to make sure that their authenticity is represented, is the thing right. ----- I'm not particularly interested in taking photographs of what you look like. Lucky for me, you already look like what you look like. Thank you very much. I'm interested in taking photos of who you are. ----- I've come up with a game that they do, which is I throw a word out at them, and they just repeat that word inside their brain. They just have to think it. So if I say to you, just with your eyes, say the word power, if you literally just think the word power, you're done. You don't have to give me what you think a powerful look is. You don't have to define power. You don't have to think of a ton you once felt powerful. Literally, I say power. You say power. I say cat, you say cat. And why does it work? It works because it keeps George inside the building. That is George, where people tend to derail themselves in photos, any photo, family photo, picture, it out with your friends. Is the second the camera comes up. Everyone tends to leave the building, right? We're in a big group of people. We say cheese. We don't know how long it's taking. We don't know how many they're taking. Our faces kind of freeze. We don't know it's, oh, it's the other camera. Are they using a flash? We get that photo back, and we hate how we look, right? You're not in that photo. You left at least 15 seconds ago, right? So that is one of the places that we derail ourselves and we don't we start to hate how we look. Now we live in a world, in this selfie culture, where you can watch yourself in the photo, right? Which is almost even worse of a problem. It makes it even more self conscious, right?  ----- ----more---- Your Intended Message is the podcast about how you can boost your career and business success by honing your communication skills. We'll examine the aspects of how we communicate one-to-one, one to few and one to many – plus that important conversation, one to self. In these interviews we will explore presentation skills, public speaking, conversation, persuasion, negotiation, sales conversations, marketing, team meetings, social media, branding, self talk and more.   Your host is George Torok George is a specialist in communication skills. Especially presentation. He's fascinated by the links between communication and influencing behaviors. He delivers training and coaching programs to help leaders and promising professionals deliver the intended message for greater success.   Connect with George www.SpeechCoachforExecutives.com https://www.linkedin.com/in/georgetorokpresentations/ https://www.youtube.com/user/presentationskills https://www.instagram.com/georgetorok/    

Scott Wapner and the Investment Committee debate big tech as Meta and Microsoft fall after earnings. Apple and Amazon on deck tonight. The desk explains their latest portfolio moves. Josh Brown and Bill Baruch also join in with their latest trades. Calls of the day include KLA Corp., Target,  and GE Healthcare.Investment Committee Disclosures

In this episode, we sit down with Ahmed Aziz Ramadi, a software engineer currently working at GE Healthcare, to hear about his journey from growing up in Tunisia to working on full-stack applications that assist healthcare professionals. Ahmed shares how he discovered his passion for computers and programming at a young age, his academic journey, and his professional experiences. He talks about his transition to the U.S. for college, the challenges of moving to a new country, and how he navigated his way into the tech industry. From his early days playing games and exploring programming, to becoming a full-stack developer working on healthcare technology, Ahmed's story is one of determination, learning, and a passion for technology.00:00 Introduction01:42 What is Ahmed Toing Today09:36 Early Memories of Working on a Computer13:00 The Influence of Parents' Engineering Careers25:00 Reflections on Family and Personal Growth32 :35 Education System53:05 Athletics and Education01:09:09 Acceptance to Purdue University01:22:17 Discovering the Tech Industry1:25:00  Joining the Workforce 1:30:00  Starting at GE Healthcare1:38:40 Contact Info  Connect with Ahmed: Linkedin: https://www.linkedin.com/in/ahmed-aziz-rmadi/Github: https://github.com/armadi1809Twitter: https://x.com/@rmadiaziz1Mentioned in today's episode:GE Healthcare – https://www.gehealthcare.com/Purdue University – https://www.purdue.edu/Want more from Ardan Labs? You can learn Go, Kubernetes, Docker & more through our video training, live events, or through our blog!Online Courses : https://ardanlabs.com/education/ Live Events : https://www.ardanlabs.com/live-training-events/ Blog : https://www.ardanlabs.com/blog Github : https://github.com/ardanlabs

This podcast is brought to you by GE HealthCare, an SNMMI Value Initiative member.  Hosts Zhiyong Lu, PhD and Jong Chul Ye, PhD speak about emerging territories in the broadening domain of Artificial Intelligence and learning about generative AI. Dr. Lu will speak the work he has done in AI in the context national language processing. Dr. Ye will speak on generative AI in imaging. 

From an internship to a full-time role at GE Healthcare, Marie Robert's journey is anything but typical. Join us as Marie, a spirited product sales specialist, opens up about her transition from a pre-med student to thriving in the medical device sales industry, with a focus on anesthesia and perioperative equipment. Her story is a testament to the power of building strategic relationships and navigating the complexities of selling capital equipment where decision-makers are not always the end users. The podcast takes a fascinating turn when we explore Marie's insights into the supportive, non-competitive environment at GE's commercial leadership program, especially during the tumultuous COVID pandemic. Listen to her experiences of working within a large corporate structure, the unique challenges of procurement-focused decision-making, and how Marie keeps ahead of the curve in a rapidly evolving industry. Marie's ability to communicate clearly with anesthesia professionals and hospital staff highlights her role's intricate dynamics, emphasizing the necessity of meaningful connections with biomedical engineers. Marie also shares her strategies for achieving work-life balance amidst the competitive landscape of medical sales. From the emotional demands of the job to the importance of self-care through activities like yoga and SoulCycle, she candidly discusses maintaining personal well-being. Her enthusiasm is infectious as she recounts memorable experiences, including industry camaraderie and competition that rivals the likes of Coke versus Pepsi. Whether you're considering a career in medical sales or just curious about the industry, Marie's story is sure to inspire and offer valuable insights into this dynamic field. Meet the guest: Marie Robert, Anesthesia sales specialist at GE Healthcare the leading vendor for anesthesia. I came through a really unique sales training program that other companies should absolutely make note of. As someone with no sales experience jumping into such a tenured industry has been a journey, and I hope this episode resonates with everyone! Connect with her: LinkedIn Best Food - Casa Della Mozzarella (https://www.instagram.com/casadellamozzarella/?hl=en) This Podcast offers a pathway to continuing education via this CMEfy link: https://earnc.me/85iljh

Welcome, Med Tech Gurus! Today, we're excited to have Brent Ness, CEO of Aclarion, with us. Brent, a seasoned medtech leader with experience at companies like GE Healthcare and Medtronic, is now guiding Aclarion's mission to transform the diagnosis of chronic low back pain. Aclarion's Nociscan technology uses MRI scans to identify chemical biomarkers in spinal discs, helping doctors pinpoint pain sources that traditional imaging often misses. Under Brent's leadership, Aclarion has achieved major milestones, including partnerships with key opinion leaders and securing insurance coverage in the UK. You will enjoy this episode as Brent shares valuable lessons and insights about commercializing disruptive technology and navigating the healthcare landscape.

Plus: GM and Ford shares fall after rival Stellantis lowers its earnings forecast. GE Healthcare shares finish higher after U.S. regulators OK an injection from the company for detecting coronary artery disease. J.R. Whalen reports.  Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Linda Chu speaks with Dr. Giuseppe Esposito, Dr. Yasar Torres-Yaghi, and Dr. Lydia Wood to explore how the availability of amyloid PET imaging and other advanced neuroimaging techniques is transforming the diagnostic and treatment landscape for neurodegenerative disorders. Sponsored by GE HealthCare.